

4th IMPAKT Breast Cancer Conference

3-5 May 2012, Brussels, Belgium

Pre-IMPAKT Training Course

PROGRAM

Wednesday, 2 May 2012

12:15-12:45 **Welcome and Lunch**

12:45-13:00	Introduction	
	Career planning in translational research	Fabrice André, FR and Sherene Loi, BE

13:00-14:00	PI3K- from mice to breast cancer patients	Chair: Sherene Loi, BE
	Biology of PI3K	Lewis Cantley, US
	PIK3CA, PTEN and AKT gene alteration in human breast cancer: Biomarkers for increased PI3K pathway activity	Bryan Hennessy, IE

14:00-15:30	Concepts in drug development: Illustration based on PI3K inhibitors	Chair: Fabrice André, FR
	Early phase drug development, a clinician's perspective	Javier Cortes, ES
	Early phase drug development, a pharma viewpoint	Malte Peters, CH
	Incorporating biomarkers into early phase clinical trials, a statistical viewpoint	Stefan Michiels, BE
	Discussion	

15:30-16:00 **Coffee break**

16:00-18:00	Translational research on Host-tumor interactions: Hot topics, experimental techniques, how, what and why with emphasis on translation	Moderator: Bryan Hennessy, IE
	Monitoring angiogenesis	Jean-Yves Pierga, FR
	Tumor-stroma interactions	Charlotte Kuperwasser, US
	Interrogating the immune system	Mark J. Smyth, AU
	Discussion	

18:00-18:30 **Cocktail**

Thursday, 3 May 2012

08:30-10:00	New technologies update (1)	Moderator: Sherene Loi, BE
	Next generation sequencing: How can it improve my research projects?	Jorge Reis-Filho, GB
	Gene expression: What's new	Christine Desmedt, BE
	MiRNA: What's new, hot topics, technologies - advantages and disadvantages	Stephan Vagner, FR

10:00-10:30 **Coffee break**

10:30-12:00	New technologies update (2)	Moderator: Fabrice André, FR
	SiRNA screens: How can it help research	Charles Swanton, GB
	Quantifying kinase activity in human samples	Thierry Dubois, FR
	Circulating tumor cells	Michail Ignatiadis, BE

12:00-13:00 **Lunch**

IMPAKT Breast Cancer Conference

PROGRAM

Thursday, 3 May 2012

11:45-12:45	Satellite symposium/Special session (TBC)	
12:00-13:00	Press Conference	
13:00-13:10	Official welcome	
	Introduction about the IMPAKT Conference	Martine Piccart, BE and José Baselga, US
	Details about the 2012 Conference	Fabrice André, FR and Sherene Loi, BE
13:10-13:55	Opening keynote lecture	Co-Chairs: Larry Norton, US and José Baselga, US
	Targeting PI3K/AKT/mTOR pathway in breast cancer	Lewis Cantley, US
	Clinical perspectives and implications for biomarker development	José Baselga, US
13:55-14:40	Recent advances in translational research – an update	Co-Chairs: Michael Gnant, AT and Hans-Jörg Senn, CH
	Update on landmark translational research breast cancer studies 2010-2011: Ready for prime time?	Martine Piccart, BE
	Update on neoadjuvant breast cancer trials 2010-2011: Lessons learnt	Gunter Von Minckwitz, DE
	Discussion	
14:40-15:40	Best abstracts session	Co-Chairs: Martine Piccart, BE and Daniel F. Hayes, US
15:40-16:20	Coffee break – Biotech walk (TBC)	
16:20-17:50	Metabolism and breast cancer	Co-Chairs: Angelo Di Leo, IT and Andrea Alimonti, CH
	Metabolism in malignant tumors: biology in breast cancer	Tak W. Mak, CA
	Insulin and IGFs: Mechanisms related to effects of diet and metformin on breast cancer	Michael N. Pollak, CA
	Implications for clinical development	Alastair Thompson, GB
	Discussion	
17:50-18:30	Challenges in biomarker and drug development: FGFR inhibitors in breast cancer	Co-Chairs: José Baselga, US and Sherene Loi, BE
	Alteration of FGFR pathway in breast cancer	Nicholas Turner, GB
	FGFR inhibitors in breast cancer	Fabrice André, FR
18:30-19:00	Welcome reception	

Friday, 4 May 2012

08:30-09:15	Keynote lecture	Co-Chairs: Mitchell Dowsett, GB and Alastair Thompson, GB
	Intratumor heterogeneity: A challenge for personalized medicine?	Charles Swanton, GB
	Clinical perspectives	Jonas Bergh, SE
09:15-10:45	Can next-generation sequencing help to solve the problem of intratumor heterogeneity?	Co-Chairs: Christophe Klein, DE and Christos Sotiriou, BE
	NGS to decipher intratumor heterogeneity	Peter Campbell, GB
	Molecular heterogeneity of the minimal residual disease	Christoph Klein, DE
	Can NGS facilitate drug development?	Matthew Ellis, US
	Discussion	
10:45-11:10	Coffee break	
11:10-12:20	Best abstracts session	Co-Chairs: Larry Norton, US and Mitchell Dowsett, GB
12:20-13:00	Lunch	
13:00-14:00	Novartis Satellite symposium	
14:00-15:00	Towards a further segmentation of triple negative breast cancer (TNBC)?	Co-Chairs: Nadia Harbeck, DE and Larry Norton, US
	Molecular characterisation of TNBC gene expression	Jorge Reis-Filho, GB
	Molecular characterisation of TNBC: the mutational landscape	Samuel Aparicio, CA
	Discussion	
15:00-16:15	Challenges in biomarker and drug development: Targeting the host and microenvironment in triple negative breast cancer?	Co-Chairs: Giuseppe Curigliano, IT and Peter C. Dubsy, AT
	Development of immunotherapeutic approaches in TNBC	Mark J. Smyth, AU
	TNBC and the relationship to its microenvironment	Charlotte Kuperwasser, US
	Lessons learnt from biomarker development in industry	Stefan Scherer, US
	Discussion	
16:15-17:20	Poster walk (<i>coffee break included in the poster walk time</i>)	
17:20-18:30	Beyond PARPi for TNBC: other drug targets	Co-Chairs: Angelo Di Leo, IT and Andrea Alimonti, CH
	Targeting DNA damage response and repair (except parp)	Thomas Helleday, GB and SE
	PTEN- a master regulator?	Andrea Alimonti, CH
	Drug development in TNBC: What did we learn from recent failures and how can we optimize future development?	Eric Winer, US
	Discussion	
18:30-19:30	Satellite symposium/Special session (TBC)	



Saturday, 5 May 2012

08:00-09:15	Can gene arrays become a standard procedure for daily practice?	Co-Chairs: Eric Winer, US and William Fraser Symmans, US
	Gene signatures: What's new to predict outcome and drug sensitivity?	Christos Sotiriou, BE
	Are whole genome arrays feasible in daily practice?	William Fraser Symmans, US
	What criteria should be met before the implementation of whole genome arrays in clinical practice?	Daniel F. Hayes, US
	Discussion	
09:15-10:15	Trends in pathology research <i>Joint session BIG-ESMO-ESP</i>	Co-Chairs: Jorge Reis-Filho, GB and Tibor Tot, SE
	New markers in pathology: Why and how	Carsten Denkert, DE
	Strategies for improving inter -and intra-laboratory concordance and reproducibility	Giuseppe Viale, IT
	Discussion	
10:15-10:30	Award session	Martine Piccart, BE and José Baselga, US
10:30-11:00	Coffee break	
11:00-13:00	Guidelines session	Co-Chairs: Sherene Loi, BE and Fabrice André, FR
	Which prognostic multigene signatures could be helpful in the daily practice?	Charles Swanton, GB
	Molecular subclasses of breast cancer: How do we define them?	Jorge Reis-Filho, GB
13:00-13:15	Closing remarks	
		Fabrice André, FR and Sherene Loi, BE
		Martine Piccart, BE and José Baselga, US